ReportWire

Tag: Medical Meetings

  • ASTRO 2023 Session Shines Spotlight on Physician Burnout

    ASTRO 2023 Session Shines Spotlight on Physician Burnout

    Newswise — MIAMI, FLORIDA (EMBARGOED UNTIL SEPT. 29, 2023, AT 5 PM ET, 2023) – Physician burnout was already a trending topic within the medical community before 2020, when the COVID-19 pandemic brought national attention to the issue.

    Typical stressors such as long hours, poor work-life balance, frustrating insurance denials and cumbersome medical documentation were compounded by new challenges from a novel, deadly virus that killed millions worldwide and necessitated a paradigm shift in care delivery.

    The side effects were widespread and readily apparent. By late 2021, research by the American Medical Association, Mayo Clinic and Stanford Medicine found that the prevalence of burnout among physicians was almost 63%, up from less than 40% the previous year. Additionally, research has repeatedly shown that occupational burnout among physicians is considerably higher than with the overall U.S. workforce.    

    So, where do things stand now? A panel of experts will delve into this topic at ASTRO 2023, the annual meeting of the American Society of Radiation Oncology, Oct. 1-4, in San Diego. The discussion, titled “Getting It All Done – Practical Strategies at All Career Stages,” occurs on Monday, Oct. 2, from 8-9 a.m., in Room 2.

    Crystal Seldon Taswell, MD, radiation oncologist and researcher with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, will co-moderate the panel discussion with Leah Katz, MD, from Columbia University College of Physicians and Surgeons.  

    Seldon Taswell and Katz will provide background on the extent of burnout within radiation oncology and medicine in general. They also will discuss the curriculum gap for residents regarding time management, balancing clinical and research work and learning boundaries for better work-life balance in an always-connected world.

    “Radiation oncology and other specialties do an excellent job of teaching resident physicians the clinical side of the job,” said Seldon Taswell, who specializes in treating breast and musculoskeletal cancers. “But often, there is a curriculum void in teaching the intangibles that ensure proper work-life integration and professional satisfaction.” 

    Seldon Taswell noted that the ASTRO panel discussion was purposely designed to offer practical strategies for practicing physicians at different stages of their careers. Panelists are:

    • Sara Beltran Ponce, MD, radiation oncology resident and mother, sharing her personal time-management tips and ways to support physician-parents.

     

    • Matt Katz, MD, physician and parent, explaining how to navigate work-life balance through various career changes and pursue academic interests in a private-practice setting.

     

    • Anthony D’amico, MD, PhD, veteran radiation oncologist and professor, offering insights into building core values into daily routines and mentoring residents/attendings as they seek balance in their lives.

     

    • Christina Henson, MD, early-career physician and parent, discussing how she navigates clinical care, research and resident teaching, as well as the challenges for women in medicine.

    “We know from research and physician surveys, in particular, that poor work-life integration is a critical driver of professional burnout,” explained Seldon Taswell. “This phenomenon can lead to higher rates of depression, drug and alcohol abuse, divorce and suicidal thoughts among physicians.”

    She added that professional burnout has potentially harmful effects on patient care, including increased medical errors, decreased patient satisfaction and strained relationships among physician colleagues.

    “Physician well-being goes hand-in-hand with the health and wellness of patients and our healthcare system in general,” Seldon Taswell said. “I look forward to participating in this important conversation at ASTRO 2023 to ensure physician wellness remains in the national spotlight.”     

    # # #

    Sylvester Comprehensive Cancer Center

    Source link

  • ISPOR Europe 2023 Plenaries and Speakers Announced

    ISPOR Europe 2023 Plenaries and Speakers Announced

    Newswise — Lawrenceville, NJ, USA—September 25, 2023—ISPOR—The Professional Society for Health Economics and Outcomes Research announced the plenary sessions and speakers for ISPOR Europe 2023. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 12-15 November in Copenhagen, Denmark with the theme, “Health Economics and Outcomes Research at the Nexus of Policy and Science.”

    Plenary sessions for ISPOR Europe 2023 include the following with speakers added to the online program as they are confirmed:

    Plenary 1: European Health Data Space – Real-World Evidence Put to Work for Public Health
    Monday, 13 November 2023
    This session will explore the proposed European Health Data Space that supports individuals taking control of their own health data, in addition to the use of health data for better healthcare delivery, better research, innovation, and policy making. It also “enables the European Union to make full use of the potential offered by a safe and secure exchange, use, and reuse of health data.” The plenary will offer multiple perspectives on the political vision and realities of a European Health Data Space. Speakers include:

    • Moderator: Steffen Thirstrup, MD, PhD; European Medicines Agency; Amsterdam, The Netherlands
    • Markus Kalliola, MSc, MSocSc; The Finnish Innovation Fund Sitra; Helsinki, Finland
    • Trine Pilgaard, MSc; Pfizer; Ballerup, Denmark
    • Patrice Verpillat, MD, MPH, PhD; European Medicines Agency; Amsterdam, The Netherlands
    • Petra Wilson, PhD; Health Connect Partners, FTI Consulting; Brussels, Belgium

    Plenary 2: The New Pharma Legislation Proposal: The Good, the Bad, or the …?
    Tuesday, 14 November 2023
    This session will discuss the proposal that the European Commission adopted for the revision of the European Union pharmaceutical legislation that aims to create a future proof regulatory framework and to support the promotion of research and technologies that fulfill patients’ therapeutic needs while addressing market failures. The panel will also discuss how and where HEOR might help with identified shortcomings or omissions in the new proposal. Speakers include:

    • Moderator: Anja Schiel, PhD; Norwegian Medicines Agency; Oslo, Norway
    • Denis Lacombe, MD; European Organisation for Research and Treatment of Cancer; Brussels, Belgium
    • Gloria Ghequiere, MEUS; Belgian Federal Government; Brussels, Belgium
    • Yannis Natsis, MA; European Public Health Alliance; Brussels, Belgium
    • Johan Pontén, MA; Medicine Evaluation Committee; Stockholm, Sweden

    Plenary 3: The Calm Before the Storm? Delivering the New Reality for EU Health Technology Assessment
    Wednesday, 15 November 2023
    This session will focus on the European Union’s health technology assessment (HTA) regulation that was adopted in January 2022 and applies as of January 2025. One of the most publicly visible components of the new regulation will be the Joint Clinical Assessments (JCAs). Panelists will discuss what the various stakeholders require of each other and how they can collectively address the anticipated challenges to ensure a smooth adoption of the new regulation. Speakers include:

    • Moderator: Adrian Griffin, MSc; Johnson & Johnson; Buckinghamshire, England, UK
    • Roisin Adams, MPharm, MSC, PhD; National Centre for Pharmacoeconomics & Discipline of Pharmacology and Therapeutics, Trinity College Dublin; Dublin, Ireland
    • Greg Rossi, PhD; AstraZeneca, Cambridge, England, UK
    • Bettina Ryll, MD, PhD; Melanoma Patient Network Europe and Past Chair of the Patient Advocates Working Group, European Society for Medical Oncology; Uppsala, Sweden
    • Jose Valverde, MD; European Commission; Brussels, Belgium

    The ISPOR Short Course Program is also being offered immediately prior to ISPOR Europe 2023 on 12 November with a wide variety of courses that range from introductory to advanced levels. All short courses do require a separate registration fee. The ISPOR Short Course Program also offers some courses virtually and the entire directory of available courses can be found here.

    ISPOR is recognized globally as the leading professional society for health economics and outcomes research and for its role in improving healthcare decisions. ISPOR Europe 2023 draws healthcare stakeholders with an interest in HEOR, including researchers and academicians, assessors and regulators, payers and policymakers, the life sciences industry, healthcare providers, and patient engagement organizations.

    Additional information on the conference can be found at: Conference Microsite | Program | Conference News Center | Press | Exhibits & Sponsorship

    ###

     

    ABOUT ISPOR
    ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
    Website  | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram  

    ISPOR–The Professional Society for Health Economics and Outcomes Research

    Source link

  • New Study Confirms HeartFlow FFRCT Leads to Improved Patient Outcomes

    New Study Confirms HeartFlow FFRCT Leads to Improved Patient Outcomes

    Newswise — CLEVELAND – A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart & Vascular Institute, has now shown through a clinical study to significantly decrease cardiovascular mortality, reduce additional non-invasive heart testing, and increase cath lab efficiency. These results show a promising, new approach that benefits not only patients’ health, but their pocketbooks.

    Developed by HeartFlow Inc., FFRCT (Fractional Flow Reserve – Computed Tomography) is the first and only non-invasive integrated heart care solution that creates a 3D model of the coronary arteries used to help physicians detect blockages, as well as identify their extent and impact on heart function. It aims to be a new standard of care for the diagnosis and management of coronary artery disease (CAD) – the number one killer worldwide. CAD affects an estimated 16.8 million American adults and is one of the most expensive medical conditions to the U.S. health care system.

    UH Harrington & Heart Vascular Institute’s Daniel Simon, MD, and Hiram Bezerra, MD, PhD were the first to use the FFRCT test in the U.S. on Jan. 16, 2015.

    “This is another example of UH Harrington Heart & Vascular Institute’s commitment to research and defining the future of medicine,” said Mehdi Shishehbor, DO, MPH, PhD, President of UH Harrington Heart & Vascular Institute, and Angela and James Hambrick Chair in Innovation. “Every day, our teams work to find new treatments and approaches to reduce cardiovascular morbidity and mortality. Eight years later, our early adoption of HeartFlow’s FFRCT technology has proven incredibly beneficial to our patients.”

    Now, promising results from a real world, multi-center, retrospective clinical study have been  released. The National Health Service England conducted the two-year FISH&CHIPS study and presented its findings at the 2023 European Society of Cardiology Congress meeting in Amsterdam.

    The study, involving more than 90,000 patients, was designed to assess at a national level the incremental impact of adding FFRCT to a CCTA-first (Coronary Computed Tomography Angiography) diagnostic pathway to evaluate and manage CAD.

    FISH&CHIPS key outcomes associated with availability of FFRCT include:

    • A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.
    • An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).
    • A 14% relative reduction in additional non-invasive heart testing following CCTA.
    • High prognostic value for FFRCT whereby patients with severely abnormal FFRCT values (≤0.50) had a 2x risk of all-cause death and a 3x risk of non-fatal MI compared to patients with normal FFRCT values.

    After performing the first American FFRCT case in 2015, Dr. Simon, then president of UH Harrington Heart & Vascular Institute, said he believed FFRCT had the potential to completely change the way CAD was managed globally.

    “FFRCT is indeed a game changer,” said Dr. Simon, now President of Academic & External Affairs and Chief Scientific Officer, and Ernie and Patti Novak Distinguished Chair in Health Care Leadership at University Hospitals, as well as Professor of Medicine and Senior Associate Dean for Academic Affairs at Case Western Reserve University School of Medicine. “This technology has changed our approach to the diagnosis of coronary artery disease. We have embraced FFRCT as the first line, preferred test because it saves lives, reduces unnecessary invasive procedures, and increases cardiac cath lab efficiency.”

    Non-invasive tests are widely used to diagnose CAD, but studies have shown a need to improve their accuracy. Most other diagnostic tests provide information regarding a patient’s overall risk of CAD, but they cannot help the clinician determine the extent to which a specific blockage is impeding blood flow to the heart. This missing piece leads to more testing and potentially more cost to the patient. HeartFlow’s FFRCT technology is designed to address this unmet need.

    “The nationwide CCTA-first approach for evaluating patients with possible cardiovascular disease has become the model of both clinical efficacy and efficiency, which is why clinical guidelines across the globe have adopted it,” said Campbell Rogers, Chief Medical Officer, HeartFlow. “FISH&CHIPS demonstrates that the decision to incorporate the HeartFlow FFRCT Analysis into patient care extended the lives of many patients and ensured efficient and effective use of noninvasive and invasive testing and treatment.”

    The recent Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) trial, which compared a non-invasive precision pathway to traditional testing, proved the CCTA+FFRCT pathway to be a more effective approach in guiding and informing treatment. FISH&CHIPS confirms and extends these results at a population level, delivering marked improvements in the hard clinical endpoints of all-cause and cardiovascular mortality, extending patients’ lives without adversely impacting other clinical events.

    ###

    About University Hospitals / Cleveland, Ohio Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 21 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio. The system’s flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University, the Technion Israel Institute of Technology and National Taiwan University College of Medicine. The main campus also includes the UH Rainbow Babies & Children’s Hospital, ranked among the top children’s hospitals in the nation; UH MacDonald Women’s Hospital, Ohio’s only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including “America’s Best Hospitals” from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH is one of the largest employers in Northeast Ohio with more than 30,000 employees. Follow UH on LinkedIn, Facebook and Twitter. For more information, visit UHhospitals.org.

     

     

     

     

    University Hospitals Cleveland Medical Center

    Source link

  • Largest Study to Date Results in Simple Genetic Risk Test for Nearly 100 Drugs Linked to Often-Fatal Side Effect in Those Being Treated for MS and Other Conditions

    Largest Study to Date Results in Simple Genetic Risk Test for Nearly 100 Drugs Linked to Often-Fatal Side Effect in Those Being Treated for MS and Other Conditions

    Key Takeaways: 

    • Researchers have identified 99 drugs used for conditions ranging from multiple sclerosis to blood cancers that may cause a rare but often-fatal condition called Progressive Multifocal Leukoencephalopathy (PML). 
    • People who have one of four recently identified genetic variants are at 10 times the risk of developing PML if they take these drugs. 
    • A simple and free genetics test can identify those who are at higher risk. 
    • Many physicians who treat these patients may be unaware of how many of these commonly prescribed drugs increase the risk of PML, which has no cure. 
    • Drug warning labels should be updated to include genetic testing before prescribing one of these drugs. 

     

    PHILADELPHIA, Sept. 11, 2023 – Nearly 100 drugs for multiple sclerosis (MS), blood cancers, rheumatoid arthritis and other diseases may cause Progressive Multifocal Leukoencephalopathy (PML), a rare but often-fatal condition. A simple genetic test can determine who has a 10-fold higher risk for the condition so they can discuss safer treatment options with their physicians. The largest study to date on drugs that increase the risk for PML and the genetic link to the disease is being presented at the 148th Annual Meeting of the American Neurological Association (ANA). 

    Researchers analyzed the Food and Drug Administration Adverse Event Reporting System (FAERS) and found 81 drugs—plus 18 more not reported to FAERS but in the same drug class as PML-linked drugs—are linked to PML deadly brain disease. Most of them are immunosuppressant disease-modifying therapies. They assessed whether the drug label listed PML risk anywhere on the label and if so, whether it was only listed as a Serious Adverse Event (SAE) or carried a Boxed Warning, the FDA’s strongest drug label warning. They note that the largest number of PML cases have been associated with natalizumab (for MS) and rituximab (for cancer and rheumatoid arthritis), both of which have a Boxed Warning. But they also found two common blood cancer drugs (daratumumab and venetoclax) have no warning on their labels of the risk of developing PML.  

    The researchers recently identified genetic variants in four genes (C8B, FCN2, LY9, STXBP2) that increase by 10-fold a person’s risk of developing PML when taking one of these drugs. All four genetic variants play a key role in immune pathways and disorders related to activating the JC virus, which lies dormant in the vast majority of people. Once activated in a person who is immune compromised, the JC virus can infect the brain and cause PML. Using a free genetic test, those who are considering taking one of those drugs can learn if they have one of the genetic variants and, if so, may consider alternative treatments that aren’t linked to PML. 

     

    A growing number of PML cases have been reported in patients on therapies for conditions including MS, Crohn’s disease, psoriasis, lupus, blood cancers, and organ transplants heightening the importance of understanding the risk and options to help prevent future cases of this devastating drug-induced side effect. 

     

    “The increased risk of drug-induced PML in patients testing positive is higher than already-known genetic associations that are used to guide treatments, like BRCA1/2 for breast cancer, yet many neurologists and oncologists may have limited awareness of how many drugs have been linked to PML,” said Peggy S. Eis, PhD, lead author of the study and chief technology officer at Population Bio, Inc., New York. “There are no treatments to cure PML, so prevention is the best defense, including knowing your genetic risk. Even though the chance of developing PML is very low for some of these drugs, patients should still be screened given the ease and low cost of doing so relative to the avoidable potential consequences for those who do test positive. Clearly, warning labels on some of these drugs need to be updated and can now include a requirement for genetic testing before these drugs are prescribed.” 

     

    She noted that patients who are currently taking those drugs should also be tested and said surveys have found patients overwhelmingly want to be tested once they know a genetic test is available.  

     

    Those testing positive for one of the genetic variants may want to consider an alternative treatment that has not been associated with PML, such as an interferon-based therapy, glatiramer acetate or teriflunomide in MS patients. In some cases, despite testing positive for one of the genes, patients may choose to stay on PML-linked therapies because they are so effective. But having knowledge of their higher genetic risk, patients and their doctors can monitor more closely for PML, such as with more frequent brain MRIs.  

     

    The researchers will present updated findings from this largest-ever PML study of its kind, including an analysis of the FAERS data, a breakdown by drug class (such as target and mechanism of action) and indication. For example, 17 of the 99 drugs are used to treat MS. It will also provide further insights into the biology of the four genes linked to PML risk and immune biology regarding how PML infects the brain (all four genes are linked to viral defense mechanisms) as well as how the genes and processes overlap with infections from the Epstein-Barr virus (EBV). For example, the STXBP2 gene (one of the four genes associated with PML) is directly linked to a type of EBV-associated disease called hemophagocytic lymphohistiocytosis.  

     

    The test for the four genetic variants associated with PML is now available free in the U.S. at https://www.pmlrisktest.org/. The test sample can be taken at home and shipped to the lab for analysis.  

     

    # # # 

    About the American Neurological Association (ANA) 

    From advances in stroke and dementia to movement disorders and epilepsy, the American Neurological Association has been the vanguard of research since 1875 as the premier professional society of academic neurologists and neuroscientists devoted to understanding and treating diseases of the nervous system. Its monthly Annals of Neurology is among the world’s most prestigious medical journals, and the ANA’s Annals of Clinical and Translational Neurology is an online-only, open access journal providing rapid dissemination of high-quality, peer-reviewed research related to all areas of neurology. The acclaimed ANA Annual Meeting draws faculty and trainees from the top academic departments across the U.S. and abroad for groundbreaking research, networking, and career development. For more information, visit www.myana.org or @TheNewANA1   

    American Neurological Association (ANA)

    Source link

  • Sleep Plays a Major Role in Neurological Disorders Getting Good Sleep May Help Reduce Risk

    Sleep Plays a Major Role in Neurological Disorders Getting Good Sleep May Help Reduce Risk

    Key Takeaways: 

    • Neurological disorders from autism spectrum disorder (ASD) to Alzheimer’s disease cause significant sleep problems. 
    • Good sleep may serve as an armor against neurological disorders. 
    • Good sleep helps children with ASD improve their brain function and behavior. 
    • Too little or too much sleep increases the risk of Alzheimer’s disease-like changes in the brain.  
    • The “glymphatic system” that cleans the brain of waste material only works during sleep. 
    • Genes may help protect “short sleepers” from Alzheimer’s disease.  

     

    PHILADELPHIA, Sept. 10, 2023 – Neurological disorders – including autism spectrum disorder (ASD), Alzheimer’s disease and Parkinson’s disease – cause sleep disturbances that make life extra challenging for people with those conditions. Improving sleep not only helps improve their quality of life, evidence is mounting that good sleep is vital for a healthy brain and may reduce the risk of some neurological disorders, according to neurologists speaking at the Presidential Symposium – Exploring Sleep Disturbances in CNS Disorders plenary session at the 148th Annual Meeting of the American Neurological Association (ANA). 

    Normal, healthy sleep is under assault by our 21st century environment – from artificial light to massive anxiety to social media – and sleep deprivation can exacerbate an existing neurological condition,” said Frances E. Jensen, MD, FANA, FACP, president of the ANA and Arthur Knight Asbury, MD Professor in Neurology and chair of the Department of Neurology at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. “Anything that affects the brain can affect sleep and vice versa. It’s important to focus on how we can improve sleep at any age because it doesn’t just keep you healthy, it can be a great armor to prevent disease.” 

    Neurological disorders including ASD, Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, REM sleep disorder, epilepsy and traumatic brain injury interfere with sleep, but the mechanism of sleep interruption varies between disorders.  

    Disrupted sleep can, in turn, exacerbate problems associated with the specific condition. Focusing on getting good sleep not only helps people with neurological conditions but may reduce the risk of developing them.  

    Neurologists suggest getting good sleep by: 

    • keeping a regular schedule for going to sleep and waking up; 
    • making sure the bedroom is dark and all the lights are off; 
    • using ear plugs and eye masks, and ensuring the bedding is comfortable; 
    • shunning caffeine after 3 p.m.; 
    • avoiding screens (TV, phone) for at least an hour before bed; 
    • napping no more than 30 minutes a day (if at all); 
    • exercising regularly, but not in the evening; 
    • avoiding eating before bedtime; and 
    • having no more than one alcoholic drink a day.  

    Sleep is Critical for Brain Development and Health in Children with ASD 

    Consistent routines and methods can help children with ASD get better sleep, which improves their executive function (planning, focus, etc.), performance on working memory tasks and daytime behavior so they are less irritable, less aggressive and have fewer meltdowns during therapy, according to information being presented during the sleep symposium. 

    More than half (50% to 80%) of children and adolescents with ASD have significant sleep problems compared to 20% to 30% of neurotypical children.1 Difficulty falling asleep, staying asleep or obstructive sleep apnea disrupt the sleep that is vital for the healthy development of young brains, including memory, learning and social-emotional development. ASD may interrupt sleep by overly arousing the brain and disrupting the normal processing of melatonin (which promotes sleep). Genetics can also play a role, as well as other medical and psychiatric conditions and medications they are taking.  

    “Parents can help their children with ASD get better sleep by ensuring they don’t ingest too much caffeine such as in soda, coffee or tea, get lots of exercise, avoid screens close to bedtime and have a bedtime routine that’s not too early,” said Beth Malow, MD, MS, FANA, who is presenting on “Sleep and Neurodevelopmental Conditions” and is director of the Sleep Division at Vanderbilt University Medical Center, Nashville. “Clinicians should also be sure there isn’t a medical condition that is waking the child. While behavioral methods should be tried first, if they don’t help enough, medications may be tried using those that target a co-occurring condition if possible, starting at a low dose that is relatively safe and effective.” 

    She noted that children with ASD often are prescribed medications for sleep, including gabapentin, alpha-adrenergic agonists, trazadone, hydroxyzine, mirtazapine, tricyclic antidepressants and others, but there is not enough research to show that they have a positive affect without causing other problems. Melatonin has the strongest track record in terms of research, but it is not regulated by the Food and Drug Administration.  

    “We need more studies with parent input to know which medications and behavioral treatments are most successful,” she said. 

    Sleep as a Factor in Alzheimer’s Disease 

    Poor sleep over long periods of time increases the risk of developing Alzheimer’s disease-type changes in the brain, suggests early research being presented during the symposium. These studies show that poor sleep accelerates changes in the brain, such as the buildup of amyloid beta plaques and tau tangles. 

    “Part of the reason that poor sleep might increase the risk of Alzheimer’s disease is related to changes to immune cells in the brain called microglia,” said David Holtzman, MD, FANA, who is presenting on the “Bidirectional Relationship Between Sleep and Alzheimer’s Disease-Related Pathology” and is scientific director of the Hope Center for Neurological Disorders and director of the Knight Alzheimer’s Disease Research Center at Washington University School of Medicine, St. Louis. “These cells are being explored as a potential target for new therapies for the disease.” 

    While researchers don’t know why Alzheimer’s disease disrupts sleep, it appears the underlying pathology affects some brain regions that control sleep. 

    “It has been shown that people who are in late middle age and cognitively normal who get low and high amounts of sleep decline faster than who get the middle ranges of sleep,” he said. “This suggests that there is an optimal range of sleep for each person that is associated with better performance over time.” 

    Sleep is Necessary to Clean the Brain, Reduce Risk of Neurological Disorders 

    The glymphatic system – which cleans the brain of waste products that increase the risk of neurological disorders – only works during sleep, which is why sleep is so important, according to a presentation at the symposium. 

    “Sleep is serious business, likely as important as exercising and avoiding smoking and excess weight gain,” said Maiken Nedergaard, MD, DMSc, who is presenting on “The Glymphatic System – and Relationship to Disorder,” and is co-director of the Center for Translational Neuromedicine, University of Rochester Medical Center, N.Y. “It’s important to develop good sleep habits because poor sleep accelerates neurological diseases and neurological diseases worsen sleep quality.” 

    The glymphatic system provides a basic housekeeping function for the brain by flushing cerebrospinal fluid into the brain during sleep to remove protein waste products, such as tau proteins and amyloid beta.  

    Gene mutations may protect short sleepers against diseases like Alzheimer’s 

    The genetic variants that enable short sleepers (those who get good sleep in four to six hours) may delay the onset and progression of Alzheimer’s-like diseases, and potentially other neurological disorders, suggests early research being presented at the symposium. 

    “The biological need for sleep varies dramatically among people,” said Ying-Hui Fu, PhD, who is presenting “Genetic Sleep Variants Protect Against Alzheimer-Like Diseases,” and is a neurology professor at the University of California at San Francisco Weill institute for Neuroscience. “Our research of familial sleep traits is beginning to shed light on how sleep is regulated and how it contributes to health.” 

    Dr. Fu’s group has identified four genes (DEC2, ADRB1, NPSR1 and GRM1) that are responsible for the ability to sleep for shorter periods of time. “We believe and predict these natural short sleep mutations can potentially protect the mutation carriers from various diseases, although we only have data for Alzheimer’s disease so far,” she said. 

    # # # 

    1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848524/#:~:text=Sleep%20disturbances%20are%20some%20of,NT)%20children4-7 

     

    About the American Neurological Association (ANA) 

    From advances in stroke and dementia to movement disorders and epilepsy, the American Neurological Association has been the vanguard of research since 1875 as the premier professional society of academic neurologists and neuroscientists devoted to understanding and treating diseases of the nervous system. Its monthly Annals of Neurology is among the world’s most prestigious medical journals, and the ANA’s Annals of Clinical and Translational Neurology is an online-only, open access journal providing rapid dissemination of high-quality, peer-reviewed research related to all areas of neurology. The acclaimed ANA Annual Meeting draws faculty and trainees from the top academic departments across the U.S. and abroad for groundbreaking research, networking, and career development. For more information, visit www.myana.org or @TheNewANA1. 

    American Neurological Association (ANA)

    Source link

  • Weight loss drug helps heart failure patients with obesity.

    Weight loss drug helps heart failure patients with obesity.

    Newswise — Amsterdam, Netherlands – 25 Aug 2023: Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.1

    Approximately half of patients with heart failure in the community have HFpEF.2 Most patients with HFpEF are overweight or obese, and growing evidence suggests that obesity and excess adiposity are not simply comorbidities, but may play a pivotal role in the development and progression of HFpEF.Patients with obesity-related HFpEF have an especially high burden of debilitating symptoms (shortness of breath, exertional intolerance, swelling/oedema) and physical limitations, which collectively result in a poor quality of life.4,5 Few treatment options are available, and there are no approved therapies specifically targeting the obesity phenotype of HFpEF.

    Semaglutide is a potent glucagon-like-peptide-1 receptor agonist which has previously been shown to produce substantial weight loss in people with overweight and obesity.6 The STEP-HFpEF trial tested the hypothesis that treatment with semaglutide can significantly improve symptoms, physical limitations and exercise function, in addition to weight loss, in patients with HFpEF and obesity.7

    STEP-HFpEF was a randomised, double-blind, placebo-controlled trial conducted at 96 sites in 13 countries in Asia, Europe, North America and South America. The trial included patients with HFpEF (left ventricular ejection fraction ≥45%), body mass index (BMI) ≥30 kg/m2, heart failure symptoms and functional limitations (New York Heart Association functional class II–IV and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score [KCCQ-CSS] <90 points).

    Participants were randomly assigned in a 1:1 ratio to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 52 weeks. The trial had two primary endpoints: change from baseline to week 52 in 1) KCCQ-CSS, a gold standard measure of heart failure-related symptoms and physical limitations; and 2) body weight. Confirmatory secondary endpoints included change in 6-minute walk distance (6MWD – a validated measure of exercise function); a hierarchical composite endpoint of death, heart failure events and change in KCCQ-CSS and 6MWD; and change in C-reactive protein (CRP – a measure of inflammation).

    The trial included 529 patients. The median age was 69 years and 56.1% were women. The median body weight and BMI at baseline were 105.1 kg and 37.0 kg/m2, respectively. At baseline, patients had a substantial degree of heart failure-related symptoms, physical limitations and poor exercise tolerance: 66.2% were NYHA class II and 33.8% were NYHA class III–IV; the median KCCQ-CSS was 58.9 points; and the median 6MWD was 320 meters.

    The trial met both primary endpoints and all confirmatory secondary endpoints. The mean change in KCCQ-CSS from baseline to week 52 was 16.6 points with semaglutide versus 8.7 points with placebo (estimated treatment difference [ETD]: 7.8 points, 95% confidence interval [CI] 4.8 to 10.9; p<0.001). The mean change in body weight from baseline to week 52 was -13.3% with semaglutide versus -2.6% with placebo (ETD: -10.7%, 95% CI -11.9% to -9.4%; p<0.001).

    Regarding secondary endpoints, the mean change in 6MWD was 21.5 meters for semaglutide versus 1.2 meters for placebo (ETD: 20.3 meters, 95% CI 8.6 to 32.1; p<0.001). For the hierarchical composite endpoint, semaglutide produced more wins than placebo (win ratio 1.72, 95% CI 1.37 to 2.15; p<0.001). The mean change in CRP was -43.5% and -7.3% with semaglutide and placebo, respectively (estimated treatment ratio 0.61, 95% CI 0.51 to 0.72; p<0.001).

    In terms of exploratory endpoints, the change in NTproBNP at 52 weeks was -20.9% and -5.3% for semaglutide versus placebo (estimated treatment ratio 0.84, 95% CI 0.71 to 0.98). One patient in the semaglutide group and 12 in the placebo group experienced an adjudicated event of heart failure hospitalisation or urgent visit (hazard ratio 0.08, 95% CI 0.00 to 0.42). Serious adverse events were reported in 35 (13.3%) and 71 (26.7%) participants with semaglutide and placebo, respectively (p<0.001).

    Principal investigator Dr. Mikhail Kosiborod of Saint Luke’s Mid America Heart Institute, Kansas City, US said: “In patients with HFpEF and obesity, treatment with semaglutide 2.4 mg produced large improvements in symptoms, physical limitations and exercise function, reduced inflammation, and resulted in greater weight loss and fewer serious adverse events as compared with placebo. To our knowledge, this is the first trial of a pharmacologic agent to specifically target obesity as a treatment strategy for HFpEF, and the magnitude of the benefits we observed is the largest seen with any agent in HFpEF. This will likely have a significant impact on clinical practice, especially since there is a dearth of efficacious therapies in this vulnerable patient group. We believe that these findings should also change the nature of the conversation about the role of obesity in HFpEF, as the STEP-HFpEF results clearly indicate that obesity is not simply a comorbidity in patients with HFpEF but a root cause and a target for therapeutic intervention.”

     

    References and notes

    1STEP-HFpEF will be discussed during Hot Line 1 on Friday 25 August at 11:15 to 12:15 CEST in room Amsterdam.

    2Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591–602.

    3Borlaug BA, Jensen MD, Kitzman DW, et al. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023;118:3434-3450.

    4Reddy YNV, Lewis GD, Shah SJ, et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. Mayo Clin Proc. 2019;94:1199–

    1209.

    5Reddy YNV, Rikhi A, Obokata M, et al. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail. 2020;22:1009–1018.

    6 Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.

    7Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients With obesity HFpEF phenotype. JACC Heart Fail. 2023;S2213-1779(23)00245-7.

    European Society of Cardiology

    Source link

  • Treating back-to-school ear infections without antibiotic resistance (video)

    Treating back-to-school ear infections without antibiotic resistance (video)

    Newswise — SAN FRANCISCO, Aug. 15, 2023 — “Back-to-school” season means buying pens and paper, figuring out the new bus route, and … earaches. Doctors typically treat these infections with antibiotics, but children don’t always complete the full course, accelerating resistance to these medications. Today, researchers report developing a single-use nanoscale system that’s unlikely to generate resistance. Using a compound similar to bleach in test animals, they show it can kill off one type of bacterium that causes ear infections, and it could someday be easily applied as a gel.

    The researchers will present their results today at the fall meeting of the American Chemical Society (ACS). ACS Fall 2023 is a hybrid meeting being held virtually and in-person Aug. 13–17, and features about 12,000 presentations on a wide range of science topics.

    A video on the research is available at www.acs.org/Earaches.

    “We initially conceived of this idea by looking at the household cleaner bleach. Even though it has been used since the 19th century, bacteria do not appear to have developed any widespread resistance to this cleaner,” says Rong Yang, Ph.D., the project’s principal investigator.

    But Yang quickly warns that people should not treat infections with bleach. The solution sold at stores is highly concentrated and caustic, but when used in a properly controlled manner at extremely low concentrations, the active ingredient in bleach is considered compatible with living tissue. 

    After realizing that the active ingredient in the household cleaner could circumvent antibiotic resistance, the researchers, who are at Cornell University, decided to tackle a nearly universal childhood scourge: acute ear infections. These infections affect more than 95% of children in the U.S., and treatment typically requires taking antibiotics for five to 10 days. However, these regimens can cause problematic side effects, leading some families to discontinue the medication prematurely, particularly if symptoms resolve. But using these medications improperly can speed up the development of antibiotic resistance, which makes infections more difficult, if not impossible, to treat. This issue ranks among the biggest threats to global health, according to the World Health Organization.

    Bacteria have more success fighting against some substances than others. Hypochloric acid from bleach belongs to a family of compounds, known as hypohalous acids, to which bacteria have yet to develop any significant resistance — most likely because of the numerous ways these highly reactive acids damage microbial cells, Yang says. 

    Because these substances break down quickly, Yang and her colleagues sought to generate one of them on an as-needed basis behind the eardrum in the middle ear, where ear infections occur. They found inspiration in an enzyme from giant kelp, which converts hydrogen peroxide (H2O2) to hypobromous acid (HOBr), a chemical relative of bleach.

    A frequent cause of ear infections, the bacterium Streptococcus pneumoniae produces H2O2 to fight off other microbes. To mimic the kelp enzyme, which contains the metal vanadium, Yang and her colleagues designed nanowires made of vanadium pentoxide (V2O5). These produce HOBr only in the presence of the H2O2-producing bacteria, and their rod-like shape helps to keep them in place by reducing their ability to diffuse into body fluids.

    In tests on chinchillas, which contract ear infections from the same pathogens as human children, they succeeded in eliminating most of the S. pneumoniae. Yang and colleagues found that after treatment with the nanowires, the animals’ once-inflamed eardrums returned to normal. Meanwhile, tests in healthy animals found evidence that the treatment did not interfere with hearing.

    For these experiments, the researchers injected the nanowires directly into the middle ear. In more recent work in chinchillas, they developed a less invasive, more practical method for delivering the wires. By decorating the nanowires with peptides known to transport small particles across the eardrum, Yang and her team found they could deliver the treatment topically as a gel deposited into the ear canal. Once the gel was applied, the nanowires within it went through the intact tissue. They are also exploring other approaches for passing the nanowires through the eardrum.

    Because other ear-infection-causing bacteria do not produce H2O2, the researchers are currently examining whether this system is effective in the presence of microbes other than S. pneumoniae, and how they might adapt it to fight the other bugs.

    The researchers have not yet done studies to determine how long the system stays in place, although their evidence suggests the nanowires drain out of the middle ear after the infection clears. However, Yang suspects they could adapt the nanowires’ properties to stay in place for long periods afterward. This latter approach could make it possible to prevent recurrent infections that plague many children.

    “If the bacteria return, the system could restart, so children wouldn’t need antibiotics repeatedly and breed more resistance along the way,” Yang says.

    The researchers acknowledge support and funding from the National Institute on Deafness and Other Communication Disorders.

    A recorded media briefing on this topic will be posted Tuesday, Aug. 15, by 10 a.m. Eastern time at www.acs.org/acsfall2023briefings.

    For health and safety information for ACS Fall 2023, please visit the FAQ webpage.

    The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and all its people. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.

    To automatically receive press releases from the American Chemical Society, contact [email protected].

    Note to journalists: Please report that this research was presented at a meeting of the American Chemical Society.

    Follow us: Twitter | Facebook | LinkedIn | Instagram

    Title
    Eradication of ear infection via autonomous synthesis of antimicrobials 

    Abstract
    Otitis media (OM) is the main reason for pediatric antibiotic prescriptions. The current treatment mandates a rigorous regimen of multidose antibiotics over 5–10 days. The systemic antibiotic exposure and often prematurely terminated treatment due to the challenge of drug administration to young patients are believed to breed antibiotic resistance. To address these challenges, we designed a local treatment that converted a metabolic product (H2O2) of an OM pathogen (Streptococcus pneumoniae) into a potent antiseptic (HOBr), a reaction catalyzed by locally administered nanozymes, i.e., vanadium pentoxide nanowires. The therapeutic, HOBr, was only synthesized in the presence of the pathogen, enabling on-demand and targeted generation of therapeutics for OM treatment. Hypohalous acids are broad-spectrum and have a long history in general disinfection applications without breeding substantial drug resistance. A single dose of the nanowire formulation eradicated OM in a standard chinchilla model in 7 days with no observable tissue toxicity or negative impact on hearing sensitivity.

    American Chemical Society (ACS)

    Source link

  • Actiphage TB awarded US Patent grant for diagnostic kit

    Actiphage TB awarded US Patent grant for diagnostic kit

    Newswise — PBD Biotech developers of Actiphage TB, a ground-breaking phage-based diagnostic for laboratory tuberculosis testing, has today announced it has secured the grant of a US patent for its diagnostic kit. The company is exhibiting in the AACC Clinical Lab Expo on booth #4578.

    Grant of this US patent relating to Mycobacteria detection using bacteriophages, and specifically to the diagnostic kit, provides further important protection for the Actiphage technology.

    Jane Theaker CEO of PBD Biotech explains: “We already have a granted US Patent for the specific method steps, but this new allowance relates to the specific components that make up the Actiphage TB diagnostic kit, strengthening our rights.”

    “We are particularly pleased with this result, claims covering diagnostic kits are notoriously difficult to obtain before the USPTO as the components of the kit are generally considered individually and not in relation to how the kit is to be used.”

    PBD Biotech is a clinical-stage diagnostic company and pioneer in phage-based diagnostics. It is focused on the development of Actiphage TB as a blood test for the detection of tuberculosis in latent TB screening and drug management.

    PBD Biotech recently initiated one of the largest clinical trials for Actiphage TB to date, building on a prior study that demonstrated detection of Mycobacteria tuberculosis (Mtb) in the blood of naive pulmonary TB patients.

    PBD Biotech is one of eight start-ups selected to present at the DxPx Conference US 2023, part of the AACC Clinical Lab Expo in Anaheim, California on July 26 2023.

    PBD is actively seeking investment and life sciences partners to support Actiphage TB clinical development and commercialization.

    DxPx is the only conference dedicated to facilitating M&A, licensing, and financing opportunities for Diagnostics, Digital Health, Precision Medicine, and Life Sciences Tools companies. 

    PBD Biotech is exhibiting in the AACC Clinical Lab Expo on Booth #4578. 

    -ENDS-

    2023 AACC Annual Scientific Meeting Press Program

    Source link

  • AACC Rebrands to the Association for Diagnostics & Laboratory Medicine

    AACC Rebrands to the Association for Diagnostics & Laboratory Medicine

    Newswise — ANAHEIM—AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a name change to the Association for Diagnostics & Laboratory Medicine. 

    This new name reflects the association’s role as advocate and champion for a larger community who specialize in diagnostics and laboratory medicine, as well as the global reach of the organization. 

    While AACC has been the professional home for clinical chemists since it began, over the years the association’s programs have grown in their appeal to other specialty areas working in or adjacent to the clinical lab. Today, the association is already broadly serving those who work in or with the clinical laboratory.

    On April 21, AACC held a member vote on the proposal to change the name of the association from AACC to the Association for Diagnostics & Laboratory Medicine (ADLM). When final votes were tabulated, the motion was carried with more than a two-thirds majority voting to approve AACC becoming the Association for Diagnostics & Laboratory Medicine.

    “I’m proud to say that this change has come about by listening to our members and focusing on the best way to ensure a bright future for our profession,” said association president Dr. Shannon Haymond. “This name change does not represent a change of direction for the association. Instead, it more accurately reflects an evolution within the field and the association that has long been underway. As we evolve into this new branding, I’d like to emphasize that the goal of the new brand is to broaden our invitation to collaborate, not narrow it.”

    ______________________________________________________________________

     

    About the Association for Diagnostics & Laboratory Medicine (ADLM) 

    Dedicated to achieving better health through laboratory medicine, ADLM (formerly AACC) brings together more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, ADLM has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.myadlm.org

    American Association for Clinical Chemistry (AACC)

    Source link

  • Researchers Identify Genes that Directly Influence What We Eat

    Researchers Identify Genes that Directly Influence What We Eat

    Newswise — In one of the first large-scale studies of genes related to diet, researchers have uncovered almost 500 genes that appear to directly influence the foods we eat. The findings represent an important step toward using a person’s genetics to develop precision nutrition strategies that help improve health or prevent disease.

    “Some genes we identified are related to sensory pathways — including those for taste, smell, and texture — and may also increase the reward response in the brain,” said research team leader Joanne Cole, PhD, assistant professor in the Department of Biomedical Informatics at the University of Colorado School of Medicine. “Because some of these genes may have clear paths toward influencing whether someone likes a food or not, they could potentially be used to create sensory genetic profiles for fine-tuning a person’s dietary recommendations based on foods they like to eat.”

    For the study, the researchers used the UK Biobank, which contains data from 500,000 people, to perform a phenome-wide association study (PheWAS) that identified genes more strongly associated with diet than with any health or lifestyle factor. PheWAS studies are used to find associations between gene variants of interest and a spectrum of human traits and behaviors, including dietary intake.

    “The foods we choose to eat are largely influenced by environmental factors such as our culture, socioeconomic status, and food accessibility,” said Cole. “Because genetics plays a much smaller role in influencing dietary intake than all the environmental factors, we need to study hundreds of thousands of individuals to detect genetic influences amid the environmental factors. The data necessary to do this hasn’t been available until recently.”

    Cole will present the findings at NUTRITION 2023, the annual flagship meeting of the American Society for Nutrition held July 22-25 in Boston.

    One challenge in identifying diet-related genes is that what people eat correlates with many other factors, including health factors such as high cholesterol or body weight and even socioeconomic status. In the new work, the researchers applied computational methods to tease out direct effects of genetic variants impacting diet and separate those from indirect effects such as ones where a gene impacts diabetes and having diabetes requires a person to eat less sugar.

    This study design was possible because the UK Biobank not only contains in-depth genetic information but also detailed health and socioeconomic data. This allowed the researchers to test individual genetic variants for associations with thousands of traits and then eliminate indirect gene variants that were more strongly associated with other factors, such as diabetes.

    The analysis revealed around 300 genes directly associated with eating specific foods and almost 200 genes linked to dietary patterns which group various foods together — for example, overall fish intake or fruit consumption.

    “The study showed that dietary patterns tend to have more indirect genetic effects, meaning they were correlated with a lot of other factors,” said Cole. “This shows how important it is to not study dietary patterns in a vacuum, because the eating pattern’s impact on human health may be completely mediated or confounded by other factors.”

    In the short term, Cole is studying the newly identified diet-related genes to better understand their function while also working to identify even more genes that directly influence food preferences. She would like to pursue several lines of translational research based on these findings. For example, she is interested in studying whether using a person’s genetics to adapt the flavor profile of a diet designed for weight loss could improve adherence.

    It might also be possible to use these new insights to tailor foods to a person’s genetic predisposition. “If we know that a gene encoding an olfactory receptor in the nose increases a person’s liking of fruit and boosts the reward response in the brain, then molecular studies of this receptor could be used to identify natural or synthetic compounds that bind to it,” Cole said. “Then, we could see if adding one of those compounds to healthy foods makes those foods more appealing to that person.”

    Cole will present this research at 2:55 p.m. on Saturday, July 22, during the Personalizing Nutrition – Genetics and Dietary Pattern Interactions Poster Theater Flash Session in the Sheraton Boston, Fairfax (abstract; presentation details).

    Please note that abstracts presented at NUTRITION 2023 were evaluated and selected by a committee of experts but have not generally undergone the same peer review process required for publication in a scientific journal. As such, the findings presented should be considered preliminary until a peer-reviewed publication is available.

     

    About NUTRITION 2023

    NUTRITION 2023 is the flagship meeting of the American Society for Nutrition and the premier educational event for nutritional professionals around the globe. NUTRITION brings together lab scientists, practicing clinicians, population health researchers, and community intervention investigators to identify solutions to today’s greatest nutrition challenges. Our audience also includes rising leaders in the field – undergraduate, graduate, and medical students. NUTRITION 2023 will be held July 22-25, 2023 in Boston. https://nutrition.org/N23 #Nutrition2023

     

    About the American Society for Nutrition (ASN)

    ASN is the preeminent professional organization for nutrition scientists and clinicians around the world. Founded in 1928, the society brings together the top nutrition researchers, medical practitioners, policy makers and industry leaders to advance our knowledge and application of nutrition. ASN publishes four peer-reviewed journals and provides education and professional development opportunities to advance nutrition research, practice, and education. Since 2018, the American Society of Nutrition has presented NUTRITION, the leading global annual meeting for nutrition professionals.

     

    Find more news briefs and tipsheets at: https://www.eurekalert.org/newsroom/nutrition2023.

     

    ###

    American Society for Nutrition (ASN)

    Source link

  • Scientists Name Top Five Foods Rich in Prebiotics

    Scientists Name Top Five Foods Rich in Prebiotics

    Newswise — There is growing evidence that consuming prebiotics — certain types of fiber often found in plants that stimulate beneficial bacteria in your gut — can help to maintain a healthy gut microbiome. In a new study, scientists estimated the prebiotic content of thousands of food types by using preexisting literature to find out which foods offer the highest prebiotic content.

    According to the study, foods that pack the greatest prebiotic punch are dandelion greens, Jerusalem artichokes, garlic, leeks, and onions. In addition to supporting gut microbes, prebiotic rich foods contain high amounts of fiber — something most Americans do not get enough of.

    “Eating prebiotic dense foods has been indicated by previous research to benefit health,” said Cassandra Boyd, a master’s student at San José State University who conducted the research with Assistant Professor John Gieng, PhD. “Eating in a way to promote microbiome wellness while eating more fiber may be more attainable and accessible than you think.”

    Boyd will present the findings at NUTRITION 2023, the flagship annual meeting of the American Society for Nutrition held July 22–25 in Boston.

    Prebiotics, which can be thought of as food for the microbiome, are different from probiotics, which contain live microorganisms. Both can potentially benefit microbiome health, but they work in different ways.

    Studies have linked higher prebiotic intake with improved blood glucose regulation, better absorption of minerals like calcium, and markers of improved digestive and immune function. Although most dietary guidelines do not currently specify a recommended daily allowance for prebiotics, the International Scientific Association for Probiotics and Prebiotics — a non-profit scientific organization that established the currently held definition of prebiotics — recommends an intake of 5 grams per day.

    For the study, researchers used previously published scientific findings to analyze the prebiotic content of 8,690 foods contained in the Food and Nutrient Database for Dietary Studies, a resource many scientists use to study nutrition and health.

    About 37% of the foods in the database were found to contain prebiotics. Dandelion greens, Jerusalem artichoke, garlic, leeks, and onions had the greatest amounts, ranging from about 100-240 milligrams of prebiotics per gram of food (mg/g). Other prebiotic rich foods included onion rings, creamed onions, cowpeas, asparagus, and Kellogg’s All-Bran cereal, each containing around 50-60 mg/g.

    “The findings from our preliminary literature review suggest that onions and related foods contain multiple forms of prebiotics, leading to a larger total prebiotic content,” said Boyd. “Multiple forms of onions and related foods appear in a variety of dishes as both flavoring and main ingredients. These foods are commonly consumed by Americans and thus would be a feasible target for people to increase their prebiotic consumption.”

    Based on the team’s findings, Boyd said a person would need to consume approximately half of a small (4-ounce) onion to get 5 grams of prebiotics.

    Wheat-containing items rank lower on the list. Foods with little or no prebiotic content include dairy products, eggs, oils, and meats.

    The researchers hope the study will provide a basis to help other scientists assess the health impacts of prebiotics and inform future dietary guidelines. They noted that more research is needed to understand how cooking impacts prebiotic content and to better assess foods that contain multiple ingredients.

    Boyd will present this research at noon EDT on Saturday, July 22, during the Food Science and Nutrition Poster Session in the Hynes Convention Center Hall C (abstract; presentation details).

    Please note that abstracts presented at NUTRITION 2023 were evaluated and selected by a committee of experts but have not generally undergone the same peer review process required for publication in a scientific journal. As such, the findings presented should be considered preliminary until a peer-reviewed publication is available.

     

    About NUTRITION 2023

    NUTRITION 2023 is the flagship meeting of the American Society for Nutrition and the premier educational event for nutritional professionals around the globe. NUTRITION brings together lab scientists, practicing clinicians, population health researchers, and community intervention investigators to identify solutions to today’s greatest nutrition challenges. Our audience also includes rising leaders in the field – undergraduate, graduate, and medical students. NUTRITION 2023 will be held July 22-25, 2023 in Boston. https://nutrition.org/N23 #Nutrition2023

     

    About the American Society for Nutrition (ASN)

    ASN is the preeminent professional organization for nutrition research scientists and clinicians around the world. Founded in 1928, the society brings together the top nutrition researchers, medical practitioners, policy makers and industry leaders to advance our knowledge and application of nutrition. ASN publishes four peer-reviewed journals and provides education and professional development opportunities to advance nutrition research, practice, and education. Since 2018, the American Society of Nutrition has presented NUTRITION, the leading global annual meeting for nutrition professionals. http://www.nutrition.org

     

    Find more news briefs from NUTRITION 2023 at: https://www.eurekalert.org/newsroom/nutrition2023.

     

    ###

    American Society for Nutrition (ASN)

    Source link

  • A Head Start on the Next Pandemic

    A Head Start on the Next Pandemic

    Newswise — BALTIMORE, July 9, 2023 – The devastating COVID-19 pandemic occurred when the SARS-CoV-2 virus, native to a species of bats, mutated to infect humans. The transition of a pathogen from only imperiling animals to threatening humans is called “spillover.”

    Investigating viruses with spillover potential could give us a head start on the next pandemic and minimize its severity. One such virus is RshTT200, discovered in Cambodian bats in 2010. RshTT200 shares 92.6% of its genomic sequence with SARS-CoV-2 and has an 85% match with COVID-19’s infamous spike protein responsible for the virus’s entry into human cells.

    During the American Crystallographic Association’s 73rd annual meeting, which will be held July 7-11 at the Baltimore Marriott Waterfront Hotel, Samantha Zepeda, from the University of Washington, will present her team’s investigation into RshTT200 to prepare for the next potential spillover event. Her presentation will take place Sunday, July 9, at 4:00 p.m. Eastern in room Waterview CD.

    Currently, a few factors prevent RshTT200 from infecting human cells. In order for the virus to spill over, it must first be able to bind to the human ACE2 receptor on the surface of human cells. The spike proteins of SARS-CoV-2 and RshTT200 are an 85% match, but that 15% difference is enough to reduce the latter’s affinity to ACE2. The receptor binding domain in the spike protein exists in both open and closed conformations, but RshTT200 more strongly favors the closed conformation, which is incompetent for receptor binding. However, this conformational ensemble could change as the RshTT200 virus mutates.

    “There are several avenues that could enable RshTT200 to pose a threat to humans,” said Zepeda. “With the help of our collaborators in the Starr Lab at the University of Utah, we identified a single nucleotide mutation that was sufficient to enable RshTT200 to enter cells after binding to the human ACE2 receptor. We also know that mutations that make the receptor binding domain more open also enable cellular entry with human ACE2.”

    To understand how viruses such as RshTT200 could infect humans, Zepeda and her team used cryo-electron microscopy to solve the spike protein structure. Once the spike proteins were understood, they built harmless, nonreplicating pseudoviruses expressing the spike proteins to investigate how RshTT200 accesses human cells.

    Their work showed not only how RshTT200 could become the next pandemic but also how we could fight it.

    “One of the most promising things this work shows is which antibodies are broadly neutralizing against RshTT200,” Zepeda said. “In the event of an outbreak, we would already know how to stabilize the spike protein for the development of vaccines and have an idea of which antibodies could be used. This would put us months ahead compared to the knowledge that was available at the beginning of the COVID-19 pandemic.”

    ###

    ———————– MORE MEETING INFORMATION ———————–

    IMPORTANT LINKS

    Main meeting website: https://www.acameeting.com/ 
    Technical program: https://www.acameeting.com/full-program

    PRESS REGISTRATION FOR MEETING SESSIONS

    We will grant free registration for credentialed and professional freelance journalists who wish to attend the meeting sessions. If you are a reporter and would like to attend, contact the AIP Media Line at [email protected]. We can also help with setting up interviews and obtaining images, sound clips or background information.

    ABOUT AMERICAN CRYSTALLOGRAPHIC ASSOCIATION

    The American Crystallographic Association, Inc. is a nonprofit, scientific organization of more than 1,000 members in more than 35 countries. The ACA was founded in 1949 through a merger of the American Society for X-Ray and Electron Diffraction (ASXRED) and the Crystallographic Society of America (CSA). The objective of the ACA is to promote interactions among scientists who study the structure of matter at atomic (or near atomic) resolution. These interactions will advance experimental and computational aspects of crystallography and diffraction. Understanding the nature of the forces that both control and result from the molecular and atomic arrangements in matter will help shed light on chemical interactions in nature.

    ###

    American Crystallographic Association (ACA)

    Source link

  • Killing Cancer in a Flash

    Killing Cancer in a Flash

    Newswise — BALTIMORE, July 8, 2023 – Radiation therapy is a common treatment used to kill cancerous cells. However, healthy cells also sustain damage during the lengthy treatment process. FLASH is a targeted radiation therapy that kills tumor cells while sparing healthy tissue. Like its namesake, FLASH delivers a short, intense burst of radiation in a single appointment. Despite this breakthrough’s proven ability, little is known about its mode of action against tumor cells.

    Corie Ralston, from Lawrence Berkeley National Laboratory, will present her team’s research using X-ray footprinting mass spectrometry to investigate the mechanisms that make FLASH a powerful cancer killer at the 73rd annual meeting of the American Crystallographic Association, which will be held July 7-11 at the Baltimore Marriott Waterfront Hotel. She will present her work Saturday, July 8, at 9:30 a.m. in room Laurel AB.

    “FLASH refers to the phenomenon that very high dose rate irradiation will spare healthy tissue around a tumor, but still kill tumor cells to the same degree as conventional dose rate radiation,” said Ralston. “The fact that this will spare healthy tissues is counterintuitive but has been demonstrated using different modes of radiation (X-ray, electron, proton) and in cells, tissues, and several animal models.”

    First discovered in 2014, FLASH treatment can be significantly more potent than conventional treatment. There are many possible explanations as to why this more intense therapy works at the cellular level. One possibility is that high dose radiation produces extremely reactive ions and molecules that selectively damage cancer cells. Alternatively, the immune system might respond differently to the dosage level.

    The research conducted by Ralston and her team points to a third theory – that a FLASH-induced low oxygen environment protects surrounding cells from further damage. At low oxygen levels, radiation induces fewer harmful modifications to proteins.

    Using X-ray footprinting mass spectrometry to map specific protein modifications in cells under varying irradiation dose rates, the team found that oxygen is consumed quickly during treatment.

    “We also found that high dose rate irradiation alters proteins less than low dose rate irradiation. This was counterintuitive, but matched the FLASH effect on healthy tissues,” Ralston said.

    Both results support the “oxygen depletion effect” and lay the groundwork for future research using the X-ray footprinting method. With more mechanistic insights gained into FLASH, tailored dosage rates and treatment plans could be developed for each cancer type or patient.

    “FLASH has generated huge interest in recent years and has been described as a breakthrough in radiation oncology,” said Ralston. “If the current clinical trials in humans hold up, then it might become the new standard of care for cancer treatment. It would mean that cancerous tumors could be treated faster and with far fewer side effects.”

    ###

    ———————– MORE MEETING INFORMATION ———————–

    IMPORTANT LINKS

    Main meeting website: https://www.acameeting.com/ 
    Technical program: https://www.acameeting.com/full-program

    PRESS REGISTRATION FOR MEETING SESSIONS

    We will grant free registration for credentialed and professional freelance journalists who wish to attend the meeting sessions. If you are a reporter and would like to attend, contact the AIP Media Line at [email protected]. We can also help with setting up interviews and obtaining images, sound clips or background information.

    ABOUT AMERICAN CRYSTALLOGRAPHIC ASSOCIATION

    The American Crystallographic Association, Inc. is a nonprofit, scientific organization of more than 1,000 members in more than 35 countries. The ACA was founded in 1949 through a merger of the American Society for X-Ray and Electron Diffraction (ASXRED) and the Crystallographic Society of America (CSA). The objective of the ACA is to promote interactions among scientists who study the structure of matter at atomic (or near atomic) resolution. These interactions will advance experimental and computational aspects of crystallography and diffraction. Understanding the nature of the forces that both control and result from the molecular and atomic arrangements in matter will help shed light on chemical interactions in nature.

    ##

    American Crystallographic Association (ACA)

    Source link

  • Racial discrimination contributes to increases in alcohol craving to cope with racial stress

    Racial discrimination contributes to increases in alcohol craving to cope with racial stress

    Newswise — Alcohol craving is associated with relapse following alcohol use disorder (AUD) treatment. A new study is the first to examine how distinct experiences of interpersonal racial discrimination contribute to elevated alcohol craving. Findings will be shared at the 46th annual scientific meeting of the Research Society on Alcohol (RSA) in Bellevue, Washington.

    “Cravings can be intense and challenging to not act on,” said Sarah L. Pedersen, associate professor of psychiatry and psychology at the University of Pittsburgh. “Research has also shown that stress increases craving for alcohol and can precipitate a lapse or relapse following AUD treatment. My team is invested in identifying influences of inequities in alcohol-related problems and, given prior research showing associations between general stress and craving, we wanted to understand how specific experiences of discrimination may increase alcohol craving.”

    Pedersen will discuss her study’s findings at the RSA meeting on Sunday, 25 June 2023.

    Data for this study were drawn from a larger ongoing alcohol administration study: 140 young adults (44% self-identified as Black or African American, 56% self-identified as White or European American) who consume alcohol at least weekly completed a survey and a 17-day assessment of acute alcohol craving as well as experienced microaggressions.

    “The Racial and Ethnic Microaggressions Scale is a 28-item self-report measure examining five domains of racial discrimination experiences during the previous six months,” explained Pedersen. “Examples include: ‘Someone told me that they don’t see color,’ ‘I was ignored at school or work because of my race,’ and ‘someone assumed I was poor because of my race.’”

    Black individuals reported higher average levels of alcohol craving across the 17-day assessment window compared to White individuals.

    Pedersen believes that experiences of interpersonal racial discrimination contribute to increases in craving alcohol to cope with racial stress. “These results have treatment implications related to promoting the development of emotion regulation skills and strategies after experiencing racial discrimination, and policy and training implications regarding the deleterious effects of exposure to interpersonal racial discrimination,” she said. Additional analyses by Pedersen’s team will integrate momentary experiences of discrimination and subsequent alcohol craving in a naturalistic environment.

    “My team uses a community-engaged approach and we have worked closely with community members to understand their needs, experiences, and ideas for research,” added Pedersen. “Our community partners are centered in our research and have been incredible contributors to this study; including the interpretation and presentation of these results.”

     

    ###

     

    Pedersen will present these findings, “Examination of interpersonal racial discrimination in relation to naturalistic alcohol craving,” during the RSA 2023 meeting in Bellevue, Washington on Sunday, 25 June 2023. More information can be found at RSoA on Twitter @RSAposts.

    Research Society on Alcoholism

    Source link

  • ATS 2024 Call for Input Deadline Approaching

    ATS 2024 Call for Input Deadline Approaching

    Newswise — The Call for Input deadline for the ATS 2024 International Conference is approaching! You have until 5 p.m. ET next Wednesday, June 28 to submit your proposals for programming in all areas of respiratory, critical care, and sleep medicine with a clinical, basic science, and/or translational focus.

    Submit your input online in the form of a session proposal in any of the following types:
    Postgraduate Course (Didactic Half-Day)
    Postgraduate Course (Didactic Full-Day)
    Postgraduate Course (Skills-Based Full-Day)
    Scientific Symposium
    Meet the Expert Seminar

    Submit Your Proposal for ATS 2024

    Deadline: 5 p.m. ET, Wednesday, June 28, 2023 

    American Thoracic Society (ATS)

    Source link

  • Oral probiotic offers potential treatment for dry eye disease

    Oral probiotic offers potential treatment for dry eye disease

    Newswise — Houston, TX –  In a study by a research group at Baylor College of Medicine, oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease in an animal model. The findings were presented at ASM Microbe 2023, the annual meeting of the American Society for Microbiology.

    Dry eye, a common condition in which tears produced by the eye can’t keep the eye adequately lubricated, afflicts approximately 1 in 20 people in the United States. It can cause eye stinging and burning, inflammation, blurry vision and light sensitivity. Extreme cases can result in damage to the eye’s surface if left untreated. The most common treatments involve the application of eye drops, gels or ointment. This new, unconventional treatment involves bacteria in the intestinal tract.

    Presenting author Laura Schaefer, Ph.D., of Baylor College of Medicine in Houston, Texas, said, “The ‘friendly’ bacteria that live in the human gastrointestinal tract have been linked to health and protection against disease in many parts of the body, including the gut, brain and lung. It’s therefore not surprising that the gut microbiome also has effects on our eyes.”

    Previous work by this research group showed that mice given gut bacteria from human Sjögren syndrome patients with severe dry eye developed worse eye disease under dry conditions than mice that were given gut bacteria from healthy human patients. This suggests that the gut bacteria from healthy people help to protect the surface of the eye in dry conditions. One possible treatment avenue for dry eye would involve probiotic bacteria that have similar protective effects. The group investigated this by using an orally administered probiotic bacterial strain, Limosilactobacillus reuteri DSM17938, in a dry eye mouse model. DSM17938 is a human-derived, commercially available probiotic bacterial strain that has already demonstrated protective effects in the gut and immune system in humans and mice, but it has not been tested in the context of eye health.

    Mice were first treated with antibiotics, which kills many of the “friendly” bacteria living in the gut. They were then exposed to very dry conditions and fed daily doses of either probiotic bacteria or a saline solution as a control. After 5 days, the eyes were examined for disease. The mice that were fed the probiotic bacteria had healthier and more intact corneal surfaces. In addition, these mice had more goblet cells in their eye tissue, which are specialized cells that produce mucin, an essential component in tears. Taken together these data suggest that the right oral probiotic could help treat and manage dry eye symptoms.

    The authors in this study are Laura Schaefer, Robert Britton, Steven Pflugfelder and Cintia de Paiva. The research was performed in the laboratory of Dr. Cintia de Paiva in the Department of Ophthalmology at Baylor College of Medicine and supported with funds from the National Institutes of Health and the Research to Prevent Blindness Foundation.
     

    ###

    American Society for Microbiology (ASM)

    Source link

  • Prompt testosterone treatment improves mental health of transgender, gender-diverse people

    Prompt testosterone treatment improves mental health of transgender, gender-diverse people

    Newswise — Receiving rapid access to testosterone therapy reduced feelings of gender dysphoria and led to a clinically significant reduction in depression as well as a 50% reduction in suicidality among transgender and gender diverse adults, according to research being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago.

    “This is the world-first randomized clinical trial supporting the significant benefits of testosterone in reducing gender dysphoria, depression and suicidality in trans individuals desiring commencement of testosterone,” said Brendan Nolan, M.B.B.S., F.R.A.C.P., a Ph.D. candidate at the University of Melbourne (Austin Health) in Melbourne, Australia. 

    Gender dysphoria occurs when a person feels distressed that their gender identity does not align with the sex assigned at birth. When an individual’s gender identity is not respected and the individual cannot access medical care, it can result in higher psychological problem scores and can raise the person’s risk of committing suicide or other acts of self-harm.

    Nolan and colleagues sought to understand the impact of testosterone therapy compared with no treatment on gender dysphoria, depression, and suicidality in trans adults seeking masculinization.

    The three-month open-label randomized controlled trial included 64 transgender adults who were able to start testosterone therapy immediately (intervention group) compared with those who were on a standard waiting list of three months prior to beginning testosterone. The purpose of this segmentation was to ensure no person would have to prolong waiting to begin treatment beyond standard care practices.

    People who were able to begin treatment immediately showed decreased gender dysphoria and a clinically significant decrease in depression and suicidal ideation compared with study participants on the wait list.

    Suicidal ideation resolved in 11 (52%) people with immediate testosterone therapy, compared with 1 (5%) given standard care, according to results from the Patient Health Questionnaire-9.

    “Our findings illustrate the significant mental health benefits of early access to testosterone treatment and should provide an impetus for clinicians to ensure timely access to gender-affirming hormone therapy,” Nolan said. 

    # # #

    Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

    The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.

    Endocrine Society

    Source link

  • Social isolation linked to reduced bone quality in males, mouse study finds

    Social isolation linked to reduced bone quality in males, mouse study finds

    Newswise — Social isolation may negatively impact bone health, suggests a study conducted in mice being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.

    “Social isolation is a potent form of psychosocial stress and is a growing public health concern, particularly among older adults,” said lead researcher Rebecca Mountain, Ph.D., of MaineHealth Institute for Research in Scarborough, Maine. “Even prior to the onset of the COVID-19 pandemic, which has significantly increased the prevalence of isolation and loneliness, researchers have been concerned about a rising ‘epidemic of loneliness.’”

    Mountain noted that social isolation is associated with increased risk for many health conditions in people, including mental health disorders, as well as higher overall rates of illness and death.

    “Previous clinical research has demonstrated that psychosocial stressors, and subsequent mental health disorders, are major risk factors for osteoporosis and fracture, which disproportionally affect older adults,” Mountain said. “The effects of social isolation on bone, however, have not been thoroughly investigated.”

    In the new study, researchers exposed adult mice to either social isolation (one mouse per cage) or grouped housing (four mice per cage) for four weeks. They found that social isolation caused significant reductions in bone quality, including reduced bone mineral density, in male, but not female mice.

    “Overall, our data suggest that social isolation has a dramatic negative effect on bone in male mice, but it may operate through different mechanisms or in a different time frame in female mice,” Mountain said. “Future research is needed to understand how these findings translate to human populations.”

    In addition to exploring the effects of social isolation in human datasets, her research team will also investigate the mechanisms of how social isolation contributes to bone loss using mouse models.

    “Our work provides critical insight into the effects of isolation on bone and has key clinical implications as we grapple with the long-term health impacts of the rise in social isolation related to the COVID-19 pandemic,” Mountain said

    # # #

    Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

    The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.

    Endocrine Society

    Source link

  • Radioactive iodine or surgery associated with increased survival in hyperthyroidism

    Radioactive iodine or surgery associated with increased survival in hyperthyroidism

    Newswise — Hyperthyroidism treatment like radioactive iodine or surgery was associated with a decreased risk for death, according to research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago.

    “Hyperthyroidism or an overactive thyroid gland is common, affecting up to 3% of the population, and is associated with long-term adverse cardiac and metabolic consequences. The optimal treatment choice remains unclear,” said Kristien Boelaert, M.D., Ph.D., a professor of endocrinology from the University of Birmingham in the United Kingdom.

    Boelaert and colleagues identified 55,318 patients with newly diagnosed hyperthyroidism, treated with antithyroid drugs (ATD; 77.6%), radioiodine (14.6%), or thyroidectomy (7.8%) from a U.K. population-based electronic health record database for the EGRET Study.

    They examined all-cause mortality, major cardiovascular events (MACE: cardiovascular death, heart failure, or stroke), and post-treatment obesity. The average follow-up was roughly 12 years.

    Those treated with antithyroid drugs had an estimated mean survival of 12 years, according to the data. Survival increased in those treated with radioiodine by 1.7 years and thyroidectomy by 1.1 years. People treated with antithyroid drugs had an estimated 10.2% risk of MACE, which significantly increased by an additional 1.3% with radioiodine but not with thyroidectomy.

    These definitive treatments were associated with a significantly increased survival, despite a small increased risk for overall weight gain. For example, thyroidectomy was associated with an increased likelihood of obesity in both men and women. Radioiodine treatment led to increased obesity risk in women, but not in men.

    “Our findings are important and will inform decision-making processes for patients and clinicians when considering optimal treatment options and are likely to impact clinical practice guidelines in the future,” Boelaert said.

    # # #

    Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

    The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.

    Endocrine Society

    Source link

  • Transgender people seen in the ER much more likely than cisgender people to be admitted to hospital

    Transgender people seen in the ER much more likely than cisgender people to be admitted to hospital

    Newswise — Transgender people who come to the emergency room for care tend to be sicker than cisgender people who are otherwise similar to them and are much more likely to be admitted to the hospital once they visit the ER, according to a study being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.

    “Our findings suggest that decreasing discrimination against transgender people in society and in health care, and improving the outpatient care they are able to access in the community, may keep them healthier and help them avoid visits to the ER,” said lead researcher Daphna Stroumsa, M.D., M.P.H., of the University of Michigan in Ann Arbor, Mich. “Improving access to transgender-friendly health care can improve the health of this population, and help decrease the burden on emergency rooms and hospitals.”

    More than 1.6 million people over the age of 13 in the United States are transgender and gender diverse. Because of social discrimination, they face many difficulties getting the health care they need, Stroumsa said. Fearing discrimination from some medical providers—a common experience among transgender people—they often avoid getting care until they are very sick. Transgender people may need to use emergency room services for basic services, or because their chronic conditions were not treated. The study examined ER visits unrelated to gender-affirming medical care.

    In the new study, the researchers analyzed data from a group of databases known as the Nationwide Emergency Department Sample. A total of 66,382 visits were made by people identified as transgender between 2006 and 2018.

    The researchers found a rapid increase in the proportion of visits by people who identified as transgender, from 0.001% of visits in 2006 to 0.016% in 2018. There were significant demographic differences between transgender and cisgender patients. Transgender and gender-diverse people were significantly more likely to be admitted, adjusting for payment, age group, region, income and mental health condition (overall 52.4% vs. 17.3%). A large proportion of ED visits by transgender and gender-diverse individuals was associated with a chronic condition (58.2% vs. 19.2%) and/or with a mental health diagnosis (28.7%, compared with 3.9% for others). Hospital admission among transgender and gender-diverse people was much more likely to be linked to a chronic condition (67.3% vs 41.3%) or a mental health condition (37.2% vs. 5.3%).

    “The high admission rates, and the high proportion of transgender and gender-diverse people with a chronic condition or with mental health condition, may represent worse overall health due lack of primary care, or a delay in seeking emergency care among transgender and gender-diverse people,” Stroumsa said. “Discrimination and transphobia have direct consequences, worsen the health of transgender people, and lead to poor use of health care resources. There is a need for increasing access to affirming primary and mental health care among transgender and gender-diverse people.”

    # # #

    Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

    The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.

    Endocrine Society

    Source link